Sniff This: Therapeutic Peptides Through the Nose?
Peptides make lousy drugs, especially for the brain. When taken as a pill or by infusion, they either bounce off the blood-brain barrier, or get degraded within minutes...
6390 RESULTS
Sort By:
Peptides make lousy drugs, especially for the brain. When taken as a pill or by infusion, they either bounce off the blood-brain barrier, or get degraded within minutes...
Limbic TDP-43 pathology accelerates cognitive decline in people with or without AD. Exosome and imaging biomarkers look promising.
Neurons need LRRK2 in order to take up tau from the extracellular milieu. In ALS neurons, tau scuppers mitochondria, whereas in healthy cells it helps the nucleolus to function correctly.
Can genetics please parse the confusing spectrum of frontotemporal dementias? Whole genome sequences make a start.
In two primary tauopathies, natural killer cells invade the brain. In Alzheimer’s, a microglial antiviral response dominates, and hyperexcitability may play a role.
Some people with severe COVID-19 have neurovascular injury and elevated markers of neural damage in their blood and CSF. What’s going on in their brains?
A chemist at the University of Cambridge, Dobson developed equations that described the kinetics of protein aggregation in diseases such as Alzheimer’s.
By Jennifer Altman, based on her original report in Alzheimer Actualités, a newsletter published by the <a href="http://www.ipsen.com/homeFondation.jsp" target="_new">Ipsen Foundation</a>...
The organizers of this year's special interest social on Alzheimer's disease decided to stage an awards ceremony to salute scientists who had distinguished themselves in various categories not ordinarily recognized...
It has been a century since Alzheimer and Bielchowsky reported senile plaques (SP) in AD brain, but it was only relatively recently appreciated that SPs are embraced by reactive astrocytes and microglia...
Last July, Dale Schenk and colleagues from Elan Pharmaceuticals reported the remarkable observation that simple immunization of PDAPP transgenic mice...
Tomlinson was the first to quantify plaques and tangles in the postmortem brain, launching the modern era of Alzheimer’s research.
In people with Alzheimer’s biomarkers, the basal forebrain shrinks early, foreshadowing microglial neurotoxicity, atrophy in the medial temporal lobe, and cognitive decline.
Alector’s AL002c antibody mobilizes microglia, reduces neuronal dystrophy, and restores normal behavior—all in mice. The clinical version is in Phase 1.
Removing cataracts cuts a person's risk of dementia. Cochlear implants stall mild cognitive impairment. Could treating sensory losses hold some dementia cases at bay?